-
1.发明公开
公开(公告)号：EP4380581A1
公开(公告)日：2024-06-12
申请号：EP22760750.4
申请日：2022-08-03
CPC分类号： A61K33/26 , A61K47/61 , A61P7/06 , A61K31/721 , A61K9/0019
-
公开(公告)号：EP1492821B1
公开(公告)日：2006-08-02
申请号：EP03746252.0
申请日：2003-04-08
IPC分类号： C08B30/18 , A61K33/26 , A61K31/715 , A61P7/06
CPC分类号： C08B30/18 , A61K31/715 , A61K33/26 , A61K2300/00
摘要： An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10 % fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90 % of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10 % fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
-
3.发明公开AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁化合物用作组件。在治疗组合物，缺铁性治疗或PROPPHYLAXE，及其制造方法
公开(公告)号：EP1066056A1
公开(公告)日：2001-01-10
申请号：EP99908785.1
申请日：1999-03-24
IPC分类号： A61K47/48
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
公开(公告)号：EP2411053A1
公开(公告)日：2012-02-01
申请号：EP09776213.2
申请日：2009-03-25
发明人： ANDREASEN, Hans
CPC分类号： C08B37/0021 , A61K47/26 , C07H3/06
摘要： The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimer saccharide in said hydrogenated oligosaccharide being 2.9 % by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.
-
5.发明授权AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁使用的化合物作为一个组件在治疗性组合物用于生产右旋糖酐铁连接及其用途用于生产肠外适用治疗制剂治疗或缺铁预防和方法。
公开(公告)号：EP1066056B2
公开(公告)日：2008-12-10
申请号：EP99908785.1
申请日：1999-03-24
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
6.发明授权AN IRON-DEXTRAN COMPOUND FOR USE AS A COMPONENT IN A THERAPEUTICAL COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IRON-DEFICIENCY, A PROCESS FOR PRODUCING SAID IRON-DEXTRAN COMPOUND AND USE OF SAID COMPOUND FOR THE PREPARATION OF A PARENTERALLY ADMINISTRABLE THERAPEUTICAL COMPOSITION 有权右旋糖酐铁使用的化合物作为一个组件在治疗性组合物用于生产右旋糖酐铁连接及其用途用于生产肠外适用治疗制剂治疗或缺铁预防和方法。
公开(公告)号：EP1066056B1
公开(公告)日：2002-07-17
申请号：EP99908785.1
申请日：1999-03-24
CPC分类号： A61K47/61
摘要： An iron-dextran compound for parenteral treatment of iron-deficiency anemia comprises hydrogenated dextran having a weight average molecular weight (Mw) between 700 and 1,400 Daltons, preferably approximately 1,000 Daltons, a number average molecular weight (Mn) of 400 to 1,400 Daltons and wherein 90 % by weight of the dextran has molecular weights less than 2,700 Daltons and the Mw of the 10 % by weight fraction of the dextran having the highest molecular weights is below 3,200 Daltons, said hydrogenated dextran having been subjected to purification by membrane processes having a cut-off value between 340 and 800 Daltons, in stable association with ferric oxyhydroxide. The compound is produced by using membrane processes to eliminate dextrans of higher molecular weights than approximately 2,700 Daltons and membrane processes to remove saccharides of molecular weights below approximately 340 Daltons from hydrogenated dextran before precipitating ferric hydroxide in the presence of said dextran followed by heat treatment and purification.
-
公开(公告)号：EP3310364B1
公开(公告)日：2021-09-15
申请号：EP16734179.1
申请日：2016-06-22
IPC分类号： A61K33/26 , A61K31/702 , A61P25/00 , A61P3/02
-
公开(公告)号：EP3212182B1
公开(公告)日：2019-06-26
申请号：EP15787128.6
申请日：2015-10-27
IPC分类号： A61K31/295 , A61K31/721 , A61P7/06
-
9.发明公开IRON CARBOHYDRATE COMPLEX FOR TREATMENT OF IRON DEFICIENCY OF A FETUS OR AN INFANT 审中-公开用于治疗胎儿或婴儿缺铁症的铁碳水化合物复合物
公开(公告)号：EP3310364A1
公开(公告)日：2018-04-25
申请号：EP16734179.1
申请日：2016-06-22
摘要： Iron carbohydrate complex for treatment of fetal metal deficiency Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
-
公开(公告)号：EP1492821A1
公开(公告)日：2005-01-05
申请号：EP03746252.0
申请日：2003-04-08
IPC分类号： C08B30/18 , A61K33/26 , A61K31/715 , A61P7/06
CPC分类号： C08B30/18 , A61K31/715 , A61K33/26 , A61K2300/00
摘要： An iron-dextrin compound for treatment of iron deficiency anaemia comprising hydrogenated dextrin having a weight average molecular weight equal to or less than 3,000 Dalton and a number average molecular weight equal to or higher than 400 Daltons, in stable association with ferric oxyhydroxide. As the molecular weight of the dextrin must be narrow it is another important feature of the invention that the 10 % fraction of the dextrins having the highest molecular weight has an average molecular weight of less than 4500 Daltons, and that 90 % of the dextrins are having molecular weights of less than 3000 Daltons. It is further important that the 10 % fraction having the lowest molecular weight has a weight average molecular weight of 340 Daltons or more.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.011 秒)
